AQR Capital Management’s NeoGenomics NEO Stock Holding History

AQR Capital Management’s Portfolio NEO Stock Details NEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.24M	Buy	167,363 +21,011	+14%	+$221K	﹤0.01%	2647
2025 Q4	$1.72M	Buy	146,352 +80,348	+122%	+$867K	﹤0.01%	2220
2025 Q3	$510K	Sell	66,004 -103,714	-61%	-$726K	﹤0.01%	2800
2025 Q2	$1.24M	Buy	169,718 +141,187	+495%	+$1.14M	﹤0.01%	2072
2025 Q1	$271K	Buy	+28,531	New	+$356K	﹤0.01%	2737
2024 Q2	–	Sell	-11,901	Closed	-$187K	–	2650
2024 Q1	$187K	Sell	11,901 -8,518	-42%	-$132K	﹤0.01%	2262
2023 Q4	$330K	Buy	20,419 +8	+0%	+$131	﹤0.01%	2036
2023 Q3	$251K	Buy	20,411 +4,532	+29%	+$67.4K	﹤0.01%	2075
2023 Q2	$255K	Buy	+15,879	New	+$262K	﹤0.01%	2000
2023 Q1	–	Sell	-15,529	Closed	-$143K	–	2226
2022 Q4	$143K	Sell	15,529 -21,147	-58%	-$197K	﹤0.01%	2107
2022 Q3	$316K	Buy	36,676 +17,536	+92%	+$174K	﹤0.01%	1931
2022 Q2	$156K	Buy	19,140 +7,042	+58%	+$67.2K	﹤0.01%	2028
2022 Q1	$147K	Sell	12,098 -1,562	-11%	-$32.9K	﹤0.01%	2104
2021 Q4	$466K	Sell	13,660 -1,517	-10%	-$59.4K	﹤0.01%	1850
2021 Q3	$732K	Hold	15,177	–	–	﹤0.01%	1708
2021 Q2	$686K	Hold	15,177	–	–	﹤0.01%	1757
2021 Q1	$732K	Sell	15,177 -27,274	-64%	-$1.42M	﹤0.01%	1688
2020 Q4	$2.29M	Sell	42,451 -32,395	-43%	-$1.46M	﹤0.01%	1105
2020 Q3	$2.76M	Sell	74,846 -33,594	-31%	-$1.25M	﹤0.01%	978
2020 Q2	$3.36M	Sell	108,440 -32,151	-23%	-$891K	0.01%	932
2020 Q1	$3.88M	Buy	140,591 +46,270	+49%	+$1.39M	0.01%	866
2019 Q4	$2.76M	Sell	94,321 -66,971	-42%	-$1.59M	﹤0.01%	1149
2019 Q3	$3.08M	Sell	161,292 -63,487	-28%	-$1.49M	﹤0.01%	1130
2019 Q2	$4.93M	Buy	224,779 +70,829	+46%	+$1.55M	0.01%	983
2019 Q1	$3.15M	Sell	153,950 -8,109	-5%	-$141K	﹤0.01%	1154
2018 Q4	$2.04M	Buy	162,059 +134,418	+486%	+$2M	﹤0.01%	1239
2018 Q3	$424K	Buy	27,641 +14,949	+118%	+$207K	﹤0.01%	2002
2018 Q2	$166K	Sell	12,692 -9,172	-42%	-$101K	﹤0.01%	2247
2018 Q1	$178K	Hold	21,864	–	–	﹤0.01%	2162
2017 Q4	$194K	Hold	21,864	–	–	﹤0.01%	2161
2017 Q3	$243K	Sell	21,864 -7,088	-24%	-$69K	﹤0.01%	2132
2017 Q2	$259K	Sell	28,952 -129	-0.4%	-$1.02K	﹤0.01%	2075
2017 Q1	$229K	Sell	29,081 -12,779	-31%	-$104K	﹤0.01%	2079
2016 Q4	$359K	Sell	41,860 -141	-0.3%	-$1.21K	﹤0.01%	2014
2016 Q3	$345K	Buy	42,001 +7,575	+22%	+$63.6K	﹤0.01%	2046
2016 Q2	$277K	Hold	34,426	–	–	﹤0.01%	2034
2016 Q1	$232K	Buy	34,426 +941	+3%	+$6.19K	﹤0.01%	2075
2015 Q4	$264K	Sell	33,485 -20,785	-38%	-$152K	﹤0.01%	2067
2015 Q3	$311K	Buy	54,270 +7,729	+17%	+$47.9K	﹤0.01%	1912
2015 Q2	$252K	Buy	46,541 +12,541	+37%	+$64.7K	﹤0.01%	2041
2015 Q1	$159K	Buy	34,000 +10,700	+46%	+$46.5K	﹤0.01%	2040
2014 Q4	$97K	Buy	23,300 +13,100	+128%	+$60.2K	﹤0.01%	2446
2014 Q3	$53K	Buy	+10,200	New	+$52.4K	﹤0.01%	2481

Other funds holding NEO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Greenhouse Funds Baltimore, Maryland $2.23B AUM 12.38% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

AQR Capital Management's NEO Position: Q1 2026 in Review

AQR Capital Management increased its NeoGenomics (NEO) stake by 14% in Q1 2026, buying an estimated $221K and bringing the position to 167,363 shares worth $1.24M. The position accounts for ﹤0.01% of the portfolio, ranked #2647.

AQR Capital Management first reported a position in NEO in Q3 2014 and has held it in 43 quarters since. The position peaked at $4.93M in Q2 2019. 253 funds tracked by Wall St. Rank hold NEO as of Q1 2026.

AQR Capital Management held 167,363 shares of NeoGenomics worth $1.24M as of Q1 2026.
AQR Capital Management bought 21,011 NeoGenomics shares in Q1 2026, an estimated $221K.
NeoGenomics made up ﹤0.01% of AQR Capital Management's portfolio in Q1 2026, its #2647 holding.
AQR Capital Management first reported a position in NeoGenomics in Q3 2014 and has held it in 43 quarters since.
AQR Capital Management's NeoGenomics position peaked at $4.93M in Q2 2019.
253 funds tracked by Wall St. Rank held NeoGenomics as of Q1 2026.

Based on AQR Capital Management's 13F filing for Q1 2026, filed 15 May 2026.